• The total number of diagnosed prevalent cases of hemophilia across the countries under study will increase by 14% from 9,707 to 11,101 in 10 years.
  • Among the countries considered in this analysis, the diagnosed prevalence of hemophilia is highest in Canada at 11.1 per 100,000.

Table of contents

  • Americas Data
    • Introduction
      • Key Findings
      • Overview
        • Prevalence of Hemophilia per 100,000 Among People of All Ages in 2017 and 2027
        • Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Hemophilia over the Next Ten Years
        • Number of Additional Prevalent Cases of Hemophilia in 2027 in the Countries Under Study due to Trends in Risk or Survival
    • Epidemiology Data
    • Methods
      • Diagnosed Prevalence
      • Severity Status
      • Inhibitor Status by Severity
      • Inhibitor Titer
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Author(s): Abey John, MPH

Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country. Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.

Related Reports

Hemophilia | Landscape & Forecast | Disease Landscape & Forecast

DRG expects the next ten years to be transitional for patients with hemophilia A, with and without inhibitors, as both the number of therapy options and the hemophilia market size will increase....

View Details

Hemophilia | Current Treatment | Detailed, Expanded Analysis (US)

Hemophilia A patients are a heterogeneous cohort. The tendency to bleed is highl...

View Details

Hemophilia | Disease Landscape and Forecast | Hemophilia A | G7 | 2019

DRG anticipates the next ten years to be a transitional time in the treatment of hemophilia A for patients with and without inhibitors. With the uptake...

View Details